Sort   by:  
 Page size 
Genomicspancreatic ductal adenocarcinoma exomes in study: Pro-immunogenic Impact of MEK inhibition combined with an anti-CD40 immunostimulatory antibody
Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression ...
EGAS00001004196 | EGA
TranscriptomicsSingle-cell RNA-sequencing of immune cells in (1) mouse Renca model treated with anti-CSF1R and (2) mouse MC38 model treated with anti-CD40
Single-cell RNA sequencing (scRNA-seq) is a powerful tool for defining cellular diversity in tumors, but its application towards dissecting mechanisms underlying immune-modulating therapies is scarce. We performed scRNA-seq analyses on immune cells in mouse tumors and identified specific macrophage ...
ORGANISM(S): Mus musculus 
2020-02-23 | E-MTAB-8832 | biostudies-arrayexpress
Genomicsena-DATASET-DKFZ-HIPO-04-02-2020-14:25:47:776-113 - samples
This dataset contains 3 pairs of exomes, germline (from whole blood) and patient-derived xenograft (PDX), from human pancreatic durctal adenocarcinoma patients. The data is referred to in the publication: "Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory a...
EGAD00001005938 | EGA
GenomicsTNF blockade uncouples toxicity and anti-tumor efficacy induced with an agonist CD40 antibody
TNF blockade uncouples toxicity and anti-tumor efficacy induced with an agonist CD40 antibody
PRJNA656939 | ENA
GenomicsPPARδ inhibition blocks tumor-induced Bregs and enhances CD40 agonist immunotherapy
PPARδ inhibition blocks tumor-induced Bregs and enhances CD40 agonist immunotherapy
PRJNA708201 | ENA
GenomicsEvaluating CD40 Agonist Alone and in Combination with IL-1R1 Blockade in Pancreatic Cancer
Evaluating CD40 Agonist Alone and in Combination with IL-1R1 Blockade in Pancreatic Cancer
PRJNA1285956 | ENA
UnknownCD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Not available
S-EPMC6683420 | biostudies-literature
ProteomicsPreclinical study with a CD40 agonist on patient-derived xenograft mice for the treatment of B-cell acute lymphoblastic leukemia
To induce leukemia in NOD/SCID/γc−/− (NSG) mice, we injected 10^5 human B-ALL cells, into the tail vein of non-irradiated mice. Two different PDX mice models were studied (PDX-1; #1 and PDX-2; #2). The InVivoMAb anti-human CD40 antibody (BE0189, clone G28.5, BioXCell) was i.v. administrated (CD40) a...
ORGANISM(S): Homo sapiens (Human) 
2024-10-10 | PXD047749 | Pride
Preclinical study Pdx models Agonist cd40 B-all leukemia Proteomic data 
TranscriptomicsIL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate and limited treatments. Agonistic CD40 antibodies are promising, but clinical trials have shown only modest efficacy and significant hepatotoxicity. We previously reported that IL-1 pathway blockade enhances CD40 agonist efficacy again...
ORGANISM(S): Mus musculus 
2026-05-22 | GSE331215 | GEO
UnknownCD40 agonist-induced IL-12p40 potentiates hepatotoxicity.
Not available
S-EPMC7264827 | biostudies-literature
Sort   by:  
 Page size